Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry

Aims: This study aimed to assess age- and sex-related differences in management and 1-year risk for all-cause mortality and hospitalization in chronic heart failure (HF) patients. Methods and results: Of 16 354 patients included in the European Society of Cardiology Heart Failure Long-Term Registry, 9428 chronic HF patients were analysed [median age: 66 years; 28.5% women; mean left ventricular ejection fraction (LVEF) 37%]. Rates of use of guideline-directed medical therapy (GDMT) were high (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists: 85.7%, 88.7% and 58.8%, respectively). Crude GDMT utilization rates were lower in women than in men (all differences: P\ua0 64 0.001), and GDMT use became lower with ageing in both sexes, at baseline and at 1-year follow-up. Sex was not an independent predictor of GDMT prescription; however, age >75 years was a significant predictor of GDMT underutilization. Rates of all-cause mortality were lower in women than in men (7.1% vs. 8.7%; P\ua0=\ua00.015), as were rates of all-cause hospitalization (21.9% vs. 27.3%; P\ua075 years. Conclusions: There was a decline in GDMT use with advanced age in both sexes. Sex was not an independent predictor of GDMT or adverse outcomes. However, age >75 years independently predicted lower GDMT use and higher all-cause mortality in patients with LVEF 6445%

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).

[No abstract available

Apixaban for Extended Treatment of Venous Thromboembolism

BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.)

Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry

none614siAims: Classification of acute heart failure (AHF) patients into four clinical profiles defined by evidence of congestion and perfusion is advocated by the 2016 European Society of Cardiology (ESC)guidelines. Based on the ESC-EORP-HFA Heart Failure Long-Term Registry, we compared differences in baseline characteristics, in-hospital management and outcomes among congestion/perfusion profiles using this classification. Methods and results: We included 7865 AHF patients classified at admission as: ‘dry-warm’ (9.9%), ‘wet-warm’ (69.9%), ‘wet-cold’ (19.8%) and ‘dry-cold’ (0.4%). These groups differed significantly in terms of baseline characteristics, in-hospital management and outcomes. In-hospital mortality was 2.0% in ‘dry-warm’, 3.8% in ‘wet-warm’, 9.1% in ‘dry-cold’ and 12.1% in ‘wet-cold’ patients. Based on clinical classification at admission, the adjusted hazard ratios (95% confidence interval) for 1-year mortality were: ‘wet-warm’ vs. ‘dry-warm’ 1.78 (1.43–2.21) and ‘wet-cold’ vs. ‘wet-warm’ 1.33 (1.19–1.48). For profiles resulting from discharge classification, the adjusted hazard ratios (95% confidence interval) for 1-year mortality were: ‘wet-warm’ vs. ‘dry-warm’ 1.46 (1.31–1.63) and ‘wet-cold’ vs. ‘wet-warm’ 2.20 (1.89–2.56). Among patients discharged alive, 30.9% had residual congestion, and these patients had higher 1-year mortality compared to patients discharged without congestion (28.0 vs. 18.5%). Tricuspid regurgitation, diabetes, anaemia and high New York Heart Association class were independently associated with higher risk of congestion at discharge, while beta-blockers at admission, de novo heart failure, or any cardiovascular procedure during hospitalization were associated with lower risk of residual congestion. Conclusion: Classification based on congestion/perfusion status provides clinically relevant information at hospital admission and discharge. A better understanding of the clinical course of the two entities could play an important role towards the implementation of targeted strategies that may improve outcomes.noneChioncel O.; Mebazaa A.; Maggioni A.P.; Harjola V.-P.; Rosano G.; Laroche C.; Piepoli M.F.; Crespo-Leiro M.G.; Lainscak M.; Ponikowski P.; Filippatos G.; Ruschitzka F.; Seferovic P.; Coats A.J.S.; Lund L.H.; Auer J.; Ablasser K.; Fruhwald F.; Dolze T.; Brandner K.; Gstrein S.; Poelzl G.; Moertl D.; Reiter S.; Podczeck-Schweighofer A.; Muslibegovic A.; Vasilj M.; Fazlibegovic E.; Cesko M.; Zelenika D.; Palic B.; Pravdic D.; Cuk D.; Vitlianova K.; Katova T.; Velikov T.; Kurteva T.; Gatzov P.; Kamenova D.; Antova M.; Sirakova V.; Krejci J.; Mikolaskova M.; Spinar J.; Krupicka J.; Malek F.; Hegarova M.; Lazarova M.; Monhart Z.; Hassanein M.; Sobhy M.; El Messiry F.; El Shazly A.H.; Elrakshy Y.; Youssef A.; Moneim A.A.; Noamany M.; Reda A.; Dayem T.K.A.; Farag N.; Halawa S.I.; Hamid M.A.; Said K.; Saleh A.; Ebeid H.; Hanna R.; Aziz R.; Louis O.; Enen M.A.; Ibrahim B.S.; Nasr G.; Elbahry A.; Sobhy H.; Ashmawy M.; Gouda M.; Aboleineen W.; Bernard Y.; Luporsi P.; Meneveau N.; Pillot M.; Morel M.; Seronde M.-F.; Schiele F.; Briand F.; Delahaye F.; Damy T.; Eicher J.-C.; de Groote P.; Fertin M.; Lamblin N.; Isnard R.; Lefol C.; Thevenin S.; Hagege A.; Jondeau G.; Logeart D.; Le Marcis V.; Ly J.-F.; Coisne D.; Lequeux B.; Le Moal V.; Mascle S.; Lotton P.; Behar N.; Donal E.; Thebault C.; Ridard C.; Reynaud A.; Basquin A.; Bauer F.; Codjia R.; Galinier M.; Tourikis P.; Stavroula M.; Tousoulis D.; Stefanadis C.; Chrysohoou C.; Kotrogiannis I.; Matzaraki V.; Dimitroula T.; Karavidas A.; Tsitsinakis G.; Kapelios C.; Nanas J.; Kampouri H.; Nana E.; Kaldara E.; Eugenidou A.; Vardas P.; Saloustros I.; Patrianakos A.; Tsaknakis T.; Evangelou S.; Nikoloulis N.; Tziourganou H.; Tsaroucha A.; Papadopoulou A.; Douras A.; Polgar L.; Merkely B.; Kosztin A.; Nyolczas N.; Nagy A.C.; Halmosi R.; Elber J.; Alony I.; Shotan A.; Fuhrmann A.V.; Amir O.; Romano S.; Marcon S.; Penco M.; Di Mauro M.; Lemme E.; Carubelli V.; Rovetta R.; Metra M.; Bulgari M.; Quinzani F.; Lombardi C.; Bosi S.; Schiavina G.; Squeri A.; Barbieri A.; Di Tano G.; Pirelli S.; Ferrari R.; Fucili A.; Passero T.; Musio S.; Di Biase M.; Correale M.; Salvemini G.; Brognoli S.; Zanelli E.; Giordano A.; Agostoni P.; Italiano G.; Salvioni E.; Copelli S.; Modena M.G.; Reggianini L.; Valenti C.; Olaru A.; Bandino S.; Deidda M.; Mercuro G.; Dessalvi C.C.; Marino P.N.; Di Ruocco M.V.; Sartori C.; Piccinino C.; Parrinello G.; Licata G.; Torres D.; Giambanco S.; Busalacchi S.; Arrotti S.; Novo S.; Inciardi R.M.; Pieri P.; Chirco P.R.; Galifi M.A.; Teresi G.; Buccheri D.; Minacapelli A.; Veniani M.; Frisinghelli A.; Priori S.G.; Cattaneo S.; Opasich C.; Gualco A.; Pagliaro M.; Mancone M.; Fedele F.; Cinque A.; Vellini M.; Scarfo I.; Romeo F.; Ferraiuolo F.; Sergi D.; Anselmi M.; Melandri F.; Leci E.; Iori E.; Bovolo V.; Pidello S.; Frea S.; Bergerone S.; Botta M.; Canavosio F.G.; Gaita F.; Merlo M.; Cinquetti M.; Sinagra G.; Ramani F.; Fabris E.; Stolfo D.; Artico J.; Miani D.; Fresco C.; Daneluzzi C.; Proclemer A.; Cicoira M.; Zanolla L.; Marchese G.; Torelli F.; Vassanelli C.; Voronina N.; Erglis A.; Tamakauskas V.; Smalinskas V.; Karaliute R.; Petraskiene I.; Kazakauskaite E.; Rumbinaite E.; Kavoliuniene A.; Vysniauskas V.; Brazyte-Ramanauskiene R.; Petraskiene D.; Stankala S.; Switala P.; Juszczyk Z.; Sinkiewicz W.; Gilewski W.; Pietrzak J.; Orzel T.; Kasztelowicz P.; Kardaszewicz P.; Lazorko-Piega M.; Gabryel J.; Mosakowska K.; Bellwon J.; Rynkiewicz A.; Raczak G.; Lewicka E.; Dabrowska-Kugacka A.; Bartkowiak R.; Sosnowska-Pasiarska B.; Wozakowska-Kaplon B.; Krzeminski A.; Zabojszcz M.; Mirek-Bryniarska E.; Grzegorzko A.; Bury K.; Nessler J.; Zalewski J.; Furman A.; Broncel M.; Poliwczak A.; Bala A.; Zycinski P.; Rudzinska M.; Jankowski L.; Kasprzak J.D.; Michalak L.; Soska K.W.; Drozdz J.; Huziuk I.; Retwinski A.; Flis P.; Weglarz J.; Bodys A.; Grajek S.; Kaluzna-Oleksy M.; Straburzynska-Migaj E.; Dankowski R.; Szymanowska K.; Grabia J.; Szyszka A.; Nowicka A.; Samcik M.; Wolniewicz L.; Baczynska K.; Komorowska K.; Poprawa I.; Komorowska E.; Sajnaga D.; Zolbach A.; Dudzik-Plocica A.; Abdulkarim A.-F.; Lauko-Rachocka A.; Kaminski L.; Kostka A.; Cichy A.; Ruszkowski P.; Splawski M.; Fitas G.; Szymczyk A.; Serwicka A.; Fiega A.; Zysko D.; Krysiak W.; Szabowski S.; Skorek E.; Pruszczyk P.; Bienias P.; Ciurzynski M.; Welnicki M.; Mamcarz A.; Folga A.; Zielinski T.; Rywik T.; Leszek P.; Sobieszczanska-Malek M.; Piotrowska M.; Kozar-Kaminska K.; Komuda K.; Wisniewska J.; Tarnowska A.; Balsam P.; Marchel M.; Opolski G.; Kaplon-Cieslicka A.; Gil R.J.; Mozenska O.; Byczkowska K.; Gil K.; Pawlak A.; Michalek A.; Krzesinski P.; Piotrowicz K.; Uzieblo-Zyczkowska B.; Stanczyk A.; Skrobowski A.; Ponikowski P.; Jankowska E.; Rozentryt P.; Polonski L.; Gadula-Gacek E.; Nowalany-Kozielska E.; Kuczaj A.; Kalarus Z.; Szulik M.; Przybylska K.; Klys J.; Prokop-Lewicka G.; Kleinrok A.; Aguiar C.T.; Ventosa A.; Pereira S.; Faria R.; Chin J.; De Jesus I.; Santos R.; Silva P.; Moreno N.; Queiros C.; Lourenco C.; Pereira A.; Castro A.; Andrade A.; Guimaraes T.O.; Martins S.; Placido R.; Lima G.; Brito D.; Francisco A.R.; Cardiga R.; Proenca M.; Araujo I.; Marques F.; Fonseca C.; Moura B.; Leite S.; Campelo M.; Silva-Cardoso J.; Rodrigues J.; Rangel I.; Martins E.; Correia A.S.; Peres M.; Marta L.; da Silva G.F.; Severino D.; Durao D.; Leao S.; Magalhaes P.; Moreira I.; Cordeiro A.F.; Ferreira C.; Araujo C.; Ferreira A.; Baptista A.; Radoi M.; Bicescu G.; Vinereanu D.; Sinescu C.-J.; Macarie C.; Popescu R.; Daha I.; Dan G.-A.; Stanescu C.; Dan A.; Craiu E.; Nechita E.; Aursulesei V.; Christodorescu R.; Otasevic P.; Seferovic P.M.; Simeunovic D.; Ristic A.D.; Celic V.; Pavlovic-Kleut M.; Lazic J.S.; Stojcevski B.; Pencic B.; Stevanovic A.; Andric A.; Iric-Cupic V.; Jovic M.; Davidovic G.; Milanov S.; Mitic V.; Atanaskovic V.; Antic S.; Pavlovic M.; Stanojevic D.; Stoickov V.; Ilic S.; Ilic M.D.; Petrovic D.; Stojsic S.; Kecojevic S.; Dodic S.; Adic N.C.; Cankovic M.; Stojiljkovic J.; Mihajlovic B.; Radin A.; Radovanovic S.; Krotin M.; Klabnik A.; Goncalvesova E.; Pernicky M.; Murin J.; Kovar F.; Kmec J.; Semjanova H.; Strasek M.; Iskra M.S.; Ravnikar T.; Suligoj N.C.; Komel J.; Fras Z.; Jug B.; Glavic T.; Losic R.; Bombek M.; Krajnc I.; Krunic B.; Horvat S.; Kovac D.; Rajtman D.; Cencic V.; Letonja M.; Winkler R.; Valentincic M.; Melihen-Bartolic C.; Bartolic A.; Vrckovnik M.P.; Kladnik M.; Pusnik C.S.; Marolt A.; Klen J.; Drnovsek B.; Leskovar B.; Anguita M.J.F.; Page J.C.G.; Martinez F.M.S.; Andres J.; Bayes-Genis A.; Mirabet S.; Mendez A.; Garcia-Cosio L.; Roig E.; Leon V.; Gonzalez-Costello J.; Muntane G.; Garay A.; Alcade-Martinez V.; Fernandez S.L.; Rivera-Lopez R.; Puga-Martinez M.; Fernandez-Alvarez M.; Serrano-Martinez J.L.; Crespo-Leiro M.; Grille-Cancela Z.; Marzoa-Rivas R.; Blanco-Canosa P.; Paniagua-Martin M.J.; Barge-Caballero E.; Cerdena I.L.; Baldomero I.F.H.; Padron A.L.; Rosillo S.O.; Gonzalez-Gallarza R.D.; Montanes O.S.; Manjavacas A.M.I.; Conde A.C.; Araujo A.; Soria T.; Garcia-Pavia P.; Gomez-Bueno M.; Cobo-Marcos M.; Alonso-Pulpon L.; Cubero J.S.; Sayago I.; Gonzalez-Segovia A.; Briceno A.; Subias P.E.; Hernandez M.V.; Cano M.J.R.; Sanchez M.A.G.; Jimenez J.F.D.; Garrido-Lestache E.B.; Pinilla J.M.G.; de la Villa B.G.; Sahuquillo A.; Marques R.B.; Calvo F.T.; Perez-Martinez M.T.; Gracia-Rodenas M.R.; Garrido-Bravo I.P.; Pastor-Perez F.; Pascual-Figal D.A.; Molina B.D.; Orus J.; Gonzalo F.E.; Bertomeu V.; Valero R.; Martinez-Abellan R.; Quiles J.; Rodrigez-Ortega J.A.; Mateo I.; ElAmrani A.; Fernandez-Vivancos C.; Valero D.B.; Almenar-Bonet L.; Sanchez-Lazaro I.J.; Marques-Sule E.; Facila-Rubio L.; Perez-Silvestre J.; Garcia-Gonzalez P.; Ridocci-Soriano F.; Garcia-Escriva D.; Pellicer-Cabo A.; de la Fuente Galan L.; Diaz J.L.; Platero A.R.; Arias J.C.; Blasco-Peiro T.; Julve M.S.; Sanchez-Insa E.; Aured-Guallar C.; Portoles-Ocampo A.; Melin M.; Hagglund E.; Stenberg A.; Lindahl I.-M.; Asserlund B.; Olsson L.; Dahlstrom U.; Afzelius M.; Karlstrom P.; Tengvall L.; Wiklund P.-A.; Olsson B.; Kalayci S.; Temizhan A.; Cavusoglu Y.; Gencer E.; Yilmaz M.B.; Gunes H.Chioncel, O.; Mebazaa, A.; Maggioni, A. P.; Harjola, V. -P.; Rosano, G.; Laroche, C.; Piepoli, M. F.; Crespo-Leiro, M. G.; Lainscak, M.; Ponikowski, P.; Filippatos, G.; Ruschitzka, F.; Seferovic, P.; Coats, A. J. S.; Lund, L. H.; Auer, J.; Ablasser, K.; Fruhwald, F.; Dolze, T.; Brandner, K.; Gstrein, S.; Poelzl, G.; Moertl, D.; Reiter, S.; Podczeck-Schweighofer, A.; Muslibegovic, A.; Vasilj, M.; Fazlibegovic, E.; Cesko, M.; Zelenika, D.; Palic, B.; Pravdic, D.; Cuk, D.; Vitlianova, K.; Katova, T.; Velikov, T.; Kurteva, T.; Gatzov, P.; Kamenova, D.; Antova, M.; Sirakova, V.; Krejci, J.; Mikolaskova, M.; Spinar, J.; Krupicka, J.; Malek, F.; Hegarova, M.; Lazarova, M.; Monhart, Z.; Hassanein, M.; Sobhy, M.; El Messiry, F.; El Shazly, A. H.; Elrakshy, Y.; Youssef, A.; Moneim, A. A.; Noamany, M.; Reda, A.; Dayem, T. K. A.; Farag, N.; Halawa, S. I.; Hamid, M. A.; Said, K.; Saleh, A.; Ebeid, H.; Hanna, R.; Aziz, R.; Louis, O.; Enen, M. A.; Ibrahim, B. S.; Nasr, G.; Elbahry, A.; Sobhy, H.; Ashmawy, M.; Gouda, M.; Aboleineen, W.; Bernard, Y.; Luporsi, P.; Meneveau, N.; Pillot, M.; Morel, M.; Seronde, M. -F.; Schiele, F.; Briand, F.; Delahaye, F.; Damy, T.; Eicher, J. -C.; de Groote, P.; Fertin, M.; Lamblin, N.; Isnard, R.; Lefol, C.; Thevenin, S.; Hagege, A.; Jondeau, G.; Logeart, D.; Le Marcis, V.; Ly, J. -F.; Coisne, D.; Lequeux, B.; Le Moal, V.; Mascle, S.; Lotton, P.; Behar, N.; Donal, E.; Thebault, C.; Ridard, C.; Reynaud, A.; Basquin, A.; Bauer, F.; Codjia, R.; Galinier, M.; Tourikis, P.; Stavroula, M.; Tousoulis, D.; Stefanadis, C.; Chrysohoou, C.; Kotrogiannis, I.; Matzaraki, V.; Dimitroula, T.; Karavidas, A.; Tsitsinakis, G.; Kapelios, C.; Nanas, J.; Kampouri, H.; Nana, E.; Kaldara, E.; Eugenidou, A.; Vardas, P.; Saloustros, I.; Patrianakos, A.; Tsaknakis, T.; Evangelou, S.; Nikoloulis, N.; Tziourganou, H.; Tsaroucha, A.; Papadopoulou, A.; Douras, A.; Polgar, L.; Merkely, B.; Kosztin, A.; Nyolczas, N.; Nagy, A. C.; Halmosi, R.; Elber, J.; Alony, I.; Shotan, A.; Fuhrmann, A. V.; Amir, O.; Romano, S.; Marcon, S.; Penco, M.; Di Mauro, M.; Lemme, E.; Carubelli, V.; Rovetta, R.; Metra, M.; Bulgari, M.; Quinzani, F.; Lombardi, C.; Bosi, S.; Schiavina, G.; Squeri, A.; Barbieri, A.; Di Tano, G.; Pirelli, S.; Ferrari, R.; Fucili, A.; Passero, T.; Musio, S.; Di Biase, M.; Correale, M.; Salvemini, G.; Brognoli, S.; Zanelli, E.; Giordano, A.; Agostoni, P.; Italiano, G.; Salvioni, E.; Copelli, S.; Modena, M. G.; Reggianini, L.; Valenti, C.; Olaru, A.; Bandino, S.; Deidda, M.; Mercuro, G.; Dessalvi, C. C.; Marino, P. N.; Di Ruocco, M. V.; Sartori, C.; Piccinino, C.; Parrinello, G.; Licata, G.; Torres, D.; Giambanco, S.; Busalacchi, S.; Arrotti, S.; Novo, S.; Inciardi, R. M.; Pieri, P.; Chirco, P. R.; Galifi, M. A.; Teresi, G.; Buccheri, D.; Minacapelli, A.; Veniani, M.; Frisinghelli, A.; Priori, S. G.; Cattaneo, S.; Opasich, C.; Gualco, A.; Pagliaro, M.; Mancone, M.; Fedele, F.; Cinque, A.; Vellini, M.; Scarfo, I.; Romeo, F.; Ferraiuolo, F.; Sergi, D.; Anselmi, M.; Melandri, F.; Leci, E.; Iori, E.; Bovolo, V.; Pidello, S.; Frea, S.; Bergerone, S.; Botta, M.; Canavosio, F. G.; Gaita, F.; Merlo, M.; Cinquetti, M.; Sinagra, G.; Ramani, F.; Fabris, E.; Stolfo, D.; Artico, J.; Miani, D.; Fresco, C.; Daneluzzi, C.; Proclemer, A.; Cicoira, M.; Zanolla, L.; Marchese, G.; Torelli, F.; Vassanelli, C.; Voronina, N.; Erglis, A.; Tamakauskas, V.; Smalinskas, V.; Karaliute, R.; Petraskiene, I.; Kazakauskaite, E.; Rumbinaite, E.; Kavoliuniene, A.; Vysniauskas, V.; Brazyte-Ramanauskiene, R.; Petraskiene, D.; Stankala, S.; Switala, P.; Juszczyk, Z.; Sinkiewicz, W.; Gilewski, W.; Pietrzak, J.; Orzel, T.; Kasztelowicz, P.; Kardaszewicz, P.; Lazorko-Piega, M.; Gabryel, J.; Mosakowska, K.; Bellwon, J.; Rynkiewicz, A.; Raczak, G.; Lewicka, E.; Dabrowska-Kugacka, A.; Bartkowiak, R.; Sosnowska-Pasiarska, B.; Wozakowska-Kaplon, B.; Krzeminski, A.; Zabojszcz, M.; Mirek-Bryniarska, E.; Grzegorzko, A.; Bury, K.; Nessler, J.; Zalewski, J.; Furman, A.; Broncel, M.; Poliwczak, A.; Bala, A.; Zycinski, P.; Rudzinska, M.; Jankowski, L.; Kasprzak, J. D.; Michalak, L.; Soska, K. W.; Drozdz, J.; Huziuk, I.; Retwinski, A.; Flis, P.; Weglarz, J.; Bodys, A.; Grajek, S.; Kaluzna-Oleksy, M.; Straburzynska-Migaj, E.; Dankowski, R.; Szymanowska, K.; Grabia, J.; Szyszka, A.; Nowicka, A.; Samcik, M.; Wolniewicz, L.; Baczynska, K.; Komorowska, K.; Poprawa, I.; Komorowska, E.; Sajnaga, D.; Zolbach, A.; Dudzik-Plocica, A.; Abdulkarim, A. -F.; Lauko-Rachocka, A.; Kaminski, L.; Kostka, A.; Cichy, A.; Ruszkowski, P.; Splawski, M.; Fitas, G.; Szymczyk, A.; Serwicka, A.; Fiega, A.; Zysko, D.; Krysiak, W.; Szabowski, S.; Skorek, E.; Pruszczyk, P.; Bienias, P.; Ciurzynski, M.; Welnicki, M.; Mamcarz, A.; Folga, A.; Zielinski, T.; Rywik, T.; Leszek, P.; Sobieszczanska-Malek, M.; Piotrowska, M.; Kozar-Kaminska, K.; Komuda, K.; Wisniewska, J.; Tarnowska, A.; Balsam, P.; Marchel, M.; Opolski, G.; Kaplon-Cieslicka, A.; Gil, R. J.; Mozenska, O.; Byczkowska, K.; Gil, K.; Pawlak, A.; Michalek, A.; Krzesinski, P.; Piotrowicz, K.; Uzieblo-Zyczkowska, B.; Stanczyk, A.; Skrobowski, A.; Ponikowski, P.; Jankowska, E.; Rozentryt, P.; Polonski, L.; Gadula-Gacek, E.; Nowalany-Kozielska, E.; Kuczaj, A.; Kalarus, Z.; Szulik, M.; Przybylska, K.; Klys, J.; Prokop-Lewicka, G.; Kleinrok, A.; Aguiar, C. T.; Ventosa, A.; Pereira, S.; Faria, R.; Chin, J.; De Jesus, I.; Santos, R.; Silva, P.; Moreno, N.; Queiros, C.; Lourenco, C.; Pereira, A.; Castro, A.; Andrade, A.; Guimaraes, T. O.; Martins, S.; Placido, R.; Lima, G.; Brito, D.; Francisco, A. R.; Cardiga, R.; Proenca, M.; Araujo, I.; Marques, F.; Fonseca, C.; Moura, B.; Leite, S.; Campelo, M.; Silva-Cardoso, J.; Rodrigues, J.; Rangel, I.; Martins, E.; Correia, A. S.; Peres, M.; Marta, L.; da Silva, G. F.; Severino, D.; Durao, D.; Leao, S.; Magalhaes, P.; Moreira, I.; Cordeiro, A. F.; Ferreira, C.; Araujo, C.; Ferreira, A.; Baptista, A.; Radoi, M.; Bicescu, G.; Vinereanu, D.; Sinescu, C. -J.; Macarie, C.; Popescu, R.; Daha, I.; Dan, G. -A.; Stanescu, C.; Dan, A.; Craiu, E.; Nechita, E.; Aursulesei, V.; Christodorescu, R.; Otasevic, P.; Seferovic, P. M.; Simeunovic, D.; Ristic, A. D.; Celic, V.; Pavlovic-Kleut, M.; Lazic, J. S.; Stojcevski, B.; Pencic, B.; Stevanovic, A.; Andric, A.; Iric-Cupic, V.; Jovic, M.; Davidovic, G.; Milanov, S.; Mitic, V.; Atanaskovic, V.; Antic, S.; Pavlovic, M.; Stanojevic, D.; Stoickov, V.; Ilic, S.; Ilic, M. D.; Petrovic, D.; Stojsic, S.; Kecojevic, S.; Dodic, S.; Adic, N. C.; Cankovic, M.; Stojiljkovic, J.; Mihajlovic, B.; Radin, A.; Radovanovic, S.; Krotin, M.; Klabnik, A.; Goncalvesova, E.; Pernicky, M.; Murin, J.; Kovar, F.; Kmec, J.; Semjanova, H.; Strasek, M.; Iskra, M. S.; Ravnikar, T.; Suligoj, N. C.; Komel, J.; Fras, Z.; Jug, B.; Glavic, T.; Losic, R.; Bombek, M.; Krajnc, I.; Krunic, B.; Horvat, S.; Kovac, D.; Rajtman, D.; Cencic, V.; Letonja, M.; Winkler, R.; Valentincic, M.; Melihen-Bartolic, C.; Bartolic, A.; Vrckovnik, M. P.; Kladnik, M.; Pusnik, C. S.; Marolt, A.; Klen, J.; Drnovsek, B.; Leskovar, B.; Anguita, M. J. F.; Page, J. C. G.; Martinez, F. M. S.; Andres, J.; Bayes-Genis, A.; Mirabet, S.; Mendez, A.; Garcia-Cosio, L.; Roig, E.; Leon, V.; Gonzalez-Costello, J.; Muntane, G.; Garay, A.; Alcade-Martinez, V.; Fernandez, S. L.; Rivera-Lopez, R.; Puga-Martinez, M.; Fernandez-Alvarez, M.; Serrano-Martinez, J. L.; Crespo-Leiro, M.; Grille-Cancela, Z.; Marzoa-Rivas, R.; Blanco-Canosa, P.; Paniagua-Martin, M. J.; Barge-Caballero, E.; Cerdena, I. L.; Baldomero, I. F. H.; Padron, A. L.; Rosillo, S. O.; Gonzalez-Gallarza, R. D.; Montanes, O. S.; Manjavacas, A. M. I.; Conde, A. C.; Araujo, A.; Soria, T.; Garcia-Pavia, P.; Gomez-Bueno, M.; Cobo-Marcos, M.; Alonso-Pulpon, L.; Cubero, J. S.; Sayago, I.; Gonzalez-Segovia, A.; Briceno, A.; Subias, P. E.; Hernandez, M. V.; Cano, M. J. R.; Sanchez, M. A. G.; Jimenez, J. F. D.; Garrido-Lestache, E. B.; Pinilla, J. M. G.; de la Villa, B. G.; Sahuquillo, A.; Marques, R. B.; Calvo, F. T.; Perez-Martinez, M. T.; Gracia-Rodenas, M. R.; Garrido-Bravo, I. P.; Pastor-Perez, F.; Pascual-Figal, D. A.; Molina, B. D.; Orus, J.; Gonzalo, F. E.; Bertomeu, V.; Valero, R.; Martinez-Abellan, R.; Quiles, J.; Rodrigez-Ortega, J. A.; Mateo, I.; Elamrani, A.; Fernandez-Vivancos, C.; Valero, D. B.; Almenar-Bonet, L.; Sanchez-Lazaro, I. J.; Marques-Sule, E.; Facila-Rubio, L.; Perez-Silvestre, J.; Garcia-Gonzalez, P.; Ridocci-Soriano, F.; Garcia-Escriva, D.; Pellicer-Cabo, A.; de la Fuente Galan, L.; Diaz, J. L.; Platero, A. R.; Arias, J. C.; Blasco-Peiro, T.; Julve, M. S.; Sanchez-Insa, E.; Aured-Guallar, C.; Portoles-Ocampo, A.; Melin, M.; Hagglund, E.; Stenberg, A.; Lindahl, I. -M.; Asserlund, B.; Olsson, L.; Dahlstrom, U.; Afzelius, M.; Karlstrom, P.; Tengvall, L.; Wiklund, P. -A.; Olsson, B.; Kalayci, S.; Temizhan, A.; Cavusoglu, Y.; Gencer, E.; Yilmaz, M. B.; Gunes, H